BrightGene Bio Valuation
| 688166 Stock | 30.92 1.21 4.07% |
At this time, the firm appears to be fairly valued. BrightGene Bio Medical shows a prevailing Real Value of USD31.65 per share. The current price of the firm is USD30.92. Our model approximates the value of BrightGene Bio Medical from analyzing the firm fundamentals such as Current Valuation of 14.72 B, return on equity of 0.06, and Profit Margin of 0.15 % as well as examining its technical indicators and probability of bankruptcy.
Price Book 5.553 | Enterprise Value 14.7 B | Enterprise Value Ebitda 70.2095 | Price Sales 10.522 | Trailing PE 68.7111 |
Fairly Valued
Today
Please note that BrightGene Bio's price fluctuation is very steady at this time. Calculation of the real value of BrightGene Bio Medical is based on 3 months time horizon. Increasing BrightGene Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BrightGene Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BrightGene Stock. However, BrightGene Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.92 | Real 31.65 | Hype 30.97 | Naive 32.64 |
The real value of BrightGene Stock, also known as its intrinsic value, is the underlying worth of BrightGene Bio Medical Company, which is reflected in its stock price. It is based on BrightGene Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BrightGene Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BrightGene Bio Medical helps investors to forecast how BrightGene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BrightGene Bio more accurately as focusing exclusively on BrightGene Bio's fundamentals will not take into account other important factors: BrightGene Bio Cash |
|
BrightGene Bio Total Value Analysis
BrightGene Bio Medical is presently estimated to have takeover price of 14.72 B with market capitalization of 13.06 B, debt of 156.87 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BrightGene Bio fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.72 B | 13.06 B | 156.87 M |
BrightGene Bio Investor Information
About 39.0% of the company shares are owned by insiders or employees . The company last dividend was issued on the 4th of July 2024. Based on the analysis of BrightGene Bio's profitability, liquidity, and operating efficiency, BrightGene Bio Medical is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 141.4 M | 224 M |
|
| |||||
| Operating Income | 177.2 M | 291.6 M |
|
|
BrightGene Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BrightGene Bio has an asset utilization ratio of 23.44 percent. This suggests that the Company is making USD0.23 for each dollar of assets. An increasing asset utilization means that BrightGene Bio Medical is more efficient with each dollar of assets it utilizes for everyday operations.BrightGene Bio Ownership Allocation
BrightGene Bio holds a total of 422.47 Million outstanding shares. BrightGene Bio Medical retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BrightGene Bio Profitability Analysis
The company reported the revenue of 1.18 B. Net Income was 200.58 M with profit before overhead, payroll, taxes, and interest of 670.14 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BrightGene Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BrightGene Bio and how it compares across the competition.
About BrightGene Bio Valuation
The stock valuation mechanism determines BrightGene Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of BrightGene Bio. We calculate exposure to BrightGene Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BrightGene Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 756.8 M | 438 M |
BrightGene Bio Quarterly Retained Earnings |
|
Complementary Tools for BrightGene Stock analysis
When running BrightGene Bio's price analysis, check to measure BrightGene Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrightGene Bio is operating at the current time. Most of BrightGene Bio's value examination focuses on studying past and present price action to predict the probability of BrightGene Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrightGene Bio's price. Additionally, you may evaluate how the addition of BrightGene Bio to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |